Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-26-016685
Filing Date
2026-02-17
Accepted
2026-02-17 21:26:03
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 10152
  Complete submission text file 0001104659-26-016685.txt   11918
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (617) 798-6700
Ernexa Therapeutics Inc. (Subject) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-42217 | Film No.: 26645014
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address ONE BOW STREET CAMBRIDGE MA 02138
Business Address
Cherington Charles (Filed by) CIK: 0001448698 (see all company filings)

Type: SCHEDULE 13D/A